Last Update Time:
05-Mar-2025 16:00:00
ISIN:
INE475E01026
Sector:
Healthcare
Symbol:
CAPLIPOINT
Caplin Point Laboratories Limited
₹1,849.50
₹39.55
(2.19%)
▲
Prev. Close
₹1,809.95
Open
₹1,800.00
Close
₹1,845.65
Range
₹1,757.03 - ₹1,941.98
High
₹1,867.00
Low
₹1,789.35
Ind. Close
₹0.00
VWAP
₹1,839.88
The current stock price of Caplin Point Laboratories Limited is ₹1,849.50, with a target price range between ₹1,757.03 and ₹1,941.98. The stock has experienced a price change of ₹39.55 (2.19%), reflecting recent market volatility.
Today's opening price was ₹1,800.00, while the previous close stood at ₹1,809.95.
The market trend suggests an uptrend, making it an attractive investment opportunity for traders seeking short-term gains.
For real-time stock market updates, live share prices, and stock analysis, stay tuned. Understanding key stock metrics like VWAP, high-low range, and market momentum can help traders make informed investment decisions.
Caplin Point Laboratories Limited Price Chart
Caplin Point Laboratories Limited Pre Open Market Overview: 05-Mar-2025
Key Metrics:
- IEP (Indicative Equilibrium Price): 1800
- Previous Close Price: 1809.95
- Change: -9.95%
- Total Traded Volume: 292
- Total Buy Quantity: 1,232
- Total Sell Quantity: 6,908
| Price | Buy Qty | Sell Qty |
|---|---|---|
| 1,790.00 | 11.00 | 0.00 |
| 1,791.00 | 1.00 | 0.00 |
| 1,795.00 | 12.00 | 0.00 |
| 1,798.00 | 3.00 | 0.00 |
| 1,799.15 | 5.00 | 0.00 |
| 1,800.00 | 0.00 | 28.00 |
| 1,801.00 | 0.00 | 1.00 |
| 1,805.00 | 0.00 | 37.00 |
| 1,807.00 | 0.00 | 40.00 |
| 1,808.90 | 0.00 | 7.00 |
ATO Data:
- Buy Quantity (ATO): 0
- Sell Quantity (ATO): 0
Order Book
| Bid | Qty | Ask | Qty |
|---|---|---|---|
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
Total Buy Quantity: 1232
Total Sell Quantity: 6908
Shareholding Patterns of Caplin Point Laboratories Limited
Key Trade Statistics of Caplin Point Laboratories Limited
| Trade Information | Details |
|---|---|
| Traded Volume (Lakhs) | 1.02 |
| Traded Value (₹ Cr.) | 18.72 |
| Total Market Cap (₹ Cr.) | 14,058.36 |
| Free Float Market Cap (₹ Cr.) | 3,725.28 |
| Impact cost | 0.06 |
| Quantity Traded | 101,765.00 |
| Deliverable Quantity | 43,892.00 |
| % of Quantity to Traded | 43.13 |
| Security VaR | 18.69 |
| Index VaR | N/A |
| VaR Margin | 18.69 |
| Extreme Loss Rate | 3.5 |
| Adhoc Margin | N/A |
| Applicable Margin Rate | 22.19 |
| Face Value | 2 |
Key Price Statistics of Caplin Point Laboratories Limited
The 52-week high for Caplin Point Laboratories Limited was ₹2,641.00, recorded on 27-Dec-2024. On the other hand, the 52-week low stands at ₹1,225.00, with the lowest value recorded on 04-Jun-2024.
The upper band for trading is ₹2,171.90, and the lower band is ₹1,448.00. The price band is 20%.
The stock's daily volatility stands at 2.86, while the annualized volatility is 54.64. The tick size for trading is ₹0.05.
| Price Information | Details |
|---|---|
| 52 Week High (27-Dec-2024) | 2,641.00 |
| 52 Week Low (04-Jun-2024) | 1,225.00 |
| Upper Band | 2,171.90 |
| Lower Band | 1,448.00 |
| Price Band (%) | 20 |
| Daily Volatility | 2.86 |
| Annualised Volatility | 54.64 |
| Tick Size | 0.05 |
Key Securities Statistics of Caplin Point Laboratories Limited
| Securities Information | Details |
|---|---|
| Status | Listed |
| Trading Status | Active |
| Date of Listing | 23-Jun-2014 |
| Adjusted P/E | 26.61 |
| Symbol P/E | 26.6 |
| Index | NIFTY 500 |
| Macro-Economic Sector | Healthcare |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Basic Industry | Pharmaceuticals |
Security Status of Caplin Point Laboratories Limited
| Title | Details |
|---|---|
| Board Status | Main |
| Trading Segment | Normal Market |
| Session No. | - |
| Class of Shares | Equity |
| SDD Compliance | - |
| Name of Compliance Officer | - |
Announcements of Caplin Point Laboratories Limited
| Subject | Date |
|---|---|
| Press Release | 26-Feb-2025 |
| Analysts/Institutional Investor Meet/Con. Call Updates | 14-Feb-2025 |
| Copy of Newspaper Publication | 08-Feb-2025 |
| Analysts/Institutional Investor Meet/Con. Call Updates | 07-Feb-2025 |
| Integrated Filing- Financial | 07-Feb-2025 |
| Financial Result Updates | 07-Feb-2025 |
| Outcome of Board Meeting | 07-Feb-2025 |
| Press Release | 05-Feb-2025 |
Corporate Actions of Caplin Point Laboratories Limited
| Face Value | Purpose | Ex-Date |
|---|---|---|
| 2 | Dividend - Rs 2.50 Per Share | 23-Sep-2024 |
| 2 | Annual General Meeting | 23-Sep-2024 |
| 2 | Interim Dividend - Rs 2.50 Per Share | 31-May-2024 |
| 2 | Annual General Meeting/Dividend - Rs 2.50 Per Share | 14-Sep-2023 |
| 2 | Interim Dividend - Rs 2 Per Share | 09-Jun-2023 |
| 2 | Annual General Meeting/Dividend - Rs 2 Per Share | 21-Sep-2022 |
| 2 | Interim Dividend - Rs 2 Per Share | 23-May-2022 |
| 2 | Annual General Meeting/Dividend - Rs 1.50 Per Share | 20-Sep-2021 |
| 2 | Interim Dividend - Rs 1.50 Per Share | 18-May-2021 |
| 2 | Annual General Meeting/Dividend - Rs 0.40 Per Share | 21-Sep-2020 |
| 2 | Interim Dividend - Rs 2.10 Per Share | 12-Mar-2020 |
| 2 | Annual General Meeting/Dividend - Rs 2.20 Per Share | 04-Sep-2019 |
| 2 | Annual General Meeting/Dividend- Rs 2 Per Share | 18-Sep-2018 |
| 2 | Annual General Meeting/Dividend - Rs 1.50 Per Share | 07-Sep-2017 |
| 2 | Fv Splt Frm Rs 10 To Rs 2 | 19-Oct-2016 |
| 2 | Annual General Meeting/Dividend - Rs 3.50 Per Share | 01-Sep-2016 |
| 2 | Interim Dividend Rs 2.50 Per Share (Purpose Revised) | 15-Feb-2016 |
| 2 | Annual General Meeting/Dividend - Rs 5/- Per Share | 29-Oct-2015 |
| 2 | Annual General Meeting / Final Dividend - Rs 4/- Per Share | 11-Dec-2014 |
Board Meetings of Caplin Point Laboratories Limited
Financial Results of Caplin Point Laboratories Limited
Company Directory of Caplin Point Laboratories Limited
| Web Address | Office | Address | City |
|---|---|---|---|
| www.caplinpoint.net | Head Office/ Corporate Office | ￃﾂￂNarbaviￃﾂￂ No. 3, Lakshmanan Street, T. Nagar, |
CHENNAI |
| www.caplinpoint.net | Registered Office | Ashvich Towers 3rd Floor, No.3, Developed Plots Industrial Estates Perungudi |
CHENNAI |
| www.caplinpoint.net | Transfer Agent | Karvy Computershare Private Limited 17-24, Vittal Rao Nagar, Madhapur, |
HYDERABAD |
Insider Trading of Caplin Point Laboratories Limited
| Reg. Clause | Acq./Disp. | Sec. Value | Txn Type |
|---|---|---|---|
| 7(2) | P Vijayalakshmi | 547363110 | Buy |
| 7(2) | Arulsudar Natrajan | 1664000 | Sell |
| 7(2) | Satish Krishnan | 4057560 | Sell |
| 7(2) | Arulsudar Natrajan | 1246500 | Sell |
| 7(2) | Subramanian Narayanaswamy | 4251975 | Sell |
| 7(2) | Arulsudar Natrajan | 1299075 | Sell |
| 7(2) | Subramanian Narayanaswamy | 87000 | Sell |
| 7(2) | Satish Kumar S | 8334 | Buy |
| 7(2) | Harikishan K | 11000 | Buy |
| 7(2) | Dinesh T | 5000 | Buy |
| 7(2) | Dinesh R | 6000 | Buy |
| 7(2) | Arul Sudar | 10000 | Buy |
| 7(2) | Anand G K | 8334 | Buy |
| 7(2) | Prem Kumar U P | 11000 | Buy |
| 7(2) | Vijayarangan R M | 5000 | Buy |
| 7(2) | Venkatachalam P | 6666 | Buy |
| 7(2) | Vamsee Krishna Tata | 5000 | Buy |
| 7(2) | Umesh Shetty | 16666 | Buy |
| 7(2) | Sundar M | 3334 | Buy |
| 7(2) | Sudhakar N | 6666 | Buy |
Annual Reports of Caplin Point Laboratories Limited
Investor Complaints of Caplin Point Laboratories Limited
Event Calendar of Caplin Point Laboratories Limited
| Purpose | Details |
|---|---|
| Results/Dividend | a) To consider and approve inter-alia Audited Financial Results of the Company for the fourth quarter and year ended June 30, 2014 b) To consider recommendation of Final Dividend for the FY 2013-14, if any. |
| Results/Others | a) to consider and approve inter-alia, the Un-Audited Financial Results of the Company for the Quarter ended 30th September, 2014 b) to consider and fix date, time and venue for the Annual General Meeting (AGM) of the Company and to fix the Book Closure date of Register of Members and Share Transfer Books, towards Final Dividend for FY 2013-14 and AGM. |
| Results | To consider and approve inter-alia, the Un-Audited Financial Results of the Company for the Quarter ended December 31, 2014. |
| Results | to consider, approve and take on record inter-alia, the Un-Audited Financial Results of the Company for the Quarter ended 31st March, 2015. |
| Results/Dividend | to consider the following:a) Audited Financial Results of the Company for the Financial year ended June 30, 2015b) Recommendation of Dividend for the FY 2014-15c) The Directors Reportd) To fix the date, time and venue of the Annual General Meeting and approve the Notice convening the Annual General Meeting e) To consider ESOS Scheme to the employees of the Company, subject to the approval of the shareholders at the ensuing Annual General Meeting.f) To Align the Financial Year of the Company (i.e) for the period of nine months from July 01, 2015 to March 31, 2016. In order to align the financial year as per the provision of Companies Act, 2013.This is for your information and records. |
| Results | Inter alia, to consider and approve the Un-audited Financial Results of the Company for the quarter ended September 30, 2015. |
| Results/Dividend | To Consider,approve and take on record interalia the Un-audited Financial Results for the quarter/half year ended December 31, 2015.To Consider and declare the payment of Interim Dividend, if any for the Financial Year 2015-16. |
| Results/Dividend | Inter-alia:1. To consider and approve the Audited Standalone and Consolidated Financial Results of the Company for Third Quarter ended March 31, 2016 and Nine Months/Financial Year Ended March 31,2016; and2 Consideration and Recommendation of Final Dividend . |
| Stock split | Inter alia, to consider the sub-division of equity shares of Rs.10/- each into equity shares with a lower face value. |
| Results | will also consider, approve and take on record the Un-audited Financial Results of the Company for the quarter ended June 30,2016. |
| Results | Inter alia to consider, approve and take on record the Un-audited Financial results for the quarter/half year ended September 30, 2016. |
| Results | Inter alia to consider, approve and take on record the Un-audited Financial Results for the quarter/nine months ended December 31,2016. |
| Results/Dividend | Inter alia, 1) To consider and approve the Audited Financial Results for the quarter/year ended March 31, 2017. 2) Recommendation of Dividend for the financial year 2016-17. |
| Results/Others | inter alia: 1.To consider, approve and take on record the Un-audited Financial Results for the first quarter ended June 30, 2017. 2.To fix the date of Annual General Meeting for the financial year 2016-17 and the matters related thereto. |
| Results | Inter alia to consider, approve and take on record the Un-audited Financial Results for the Second Quarter/half year ended September 30, 2017. |
| Results | Inter alia to consider and take on record the Un-audited Financial Results for third quarter/nine months ended December 31,2017. |
| Other business matters | To consider other business matters |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2018 and dividend |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2018 |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2018 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2018 |
| Other business matters | To consider other business matters |
| Other business matters | To consider other business matters |
| Other business matters | inter-alia, to consider and approve the Investment by a global financial investor with strong healthcare experience in the Wholly Owned Subsidiary Company, Caplin Steriles Limited. |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2018 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2019 and dividend |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2019 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2019 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2019 |
| Dividend | To consider Interim Dividend |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2020 and dividend |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2020 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2020 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2020 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2021 and dividend |
| Financial Results/Dividend | To consider and approve the financial results for the period ended Jun 30, 2021 and dividend |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2021 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2021 |
| Financial results | Caplin Point Laboratories Limited has informed the Exchange about Board Meeting to be held on 12-Nov-2022 to consider financial statements for the period ended September 2022 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2022 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2023 and dividend |
| Financial Results/Dividend | CAPLIPOINT : 27-May-2023 : The Company has informed the Exchange that a Board meeting to be held on May 24, 2023 has been re-scheduled. Further, the Company has informed the Exchange that the meeting of the Board of Directors of the Company will be held on May 27, 2023, To consider and approve the financial results for the period ended March 31, 2023 and dividend |
| Financial Results/Dividend | 1) Quarterly unaudited financial results for the quarter ended June 30, 2023 (both standalone & consolidated); 2) Recommendation of Final Dividend for the FY 2022-23 for approval of shareholders; 3) Convening the Annual General Meeting of the Company; and4) Fixation of record date for determining the eligibility of shareholders entitled for the Final Dividend. |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2023 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2023 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2024 and dividend |
| Financial Results/Dividend | To consider and approve the financial results for the period ended Jun 30, 2024 and final dividend |
| Financial Results | To consider and approve, inter-alia the un-audited financial results of the Company for the quarter and half-year ended September 30, 2024 (both standalone & consolidated). |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2024 |
Share Transfers of Caplin Point Laboratories Limited
Voting Results of Caplin Point Laboratories Limited
| Date of Mtg. | Mtg. Type | Resolution |
|---|---|---|
| 30-SEP-2024 | AGM | To receive, consider and adopt the Audited Standalone and Consolidated Financial Statements of the Company for the year ended March 31, 2024 along with the Reports of the Board of Director￢ﾀﾙs and the Auditor￢ﾀﾙs thereon |
| 30-SEP-2024 | AGM | To consider and approve the Appointment of Mr R Vijayaraghavan as an Independent Director of the Company. |
| 30-SEP-2024 | AGM | Re-appointment of Dr Sridhar Ganesan as the Managing Director of the Company. |
| 30-SEP-2024 | AGM | To approve Fresh Material Related Party Transaction(s) / Contract(s) / Arrangement(s) |
| 30-SEP-2024 | AGM | To re-appoint Dr. Sridhar Ganesan (DIN: 06819026) who retires by rotation, and being eligible, offers himself for re-appointment |
| 30-SEP-2024 | AGM | To declare final dividend and ratification of interim dividend |
| 21-SEP-2023 | AGM | To receive, consider and adopt the Audited Standalone and Consolidated Financial Statements of the Company for the year ended March 31, 2023 along with the Reports of the Board of Director￢ﾀﾙs and the Auditor￢ﾀﾙs thereon. |
| 21-SEP-2023 | AGM | To re-appoint Dr. Gariyali as an Independent Director |
| 21-SEP-2023 | AGM | To approve material modifications to earlier approved Material Related Party Transaction(s)/Contract(s)/Arrangement(s). |
| 21-SEP-2023 | AGM | To appoint M/S Brahmayya and Co, Charted Accountants as the statutory auditors of the company |
| 21-SEP-2023 | AGM | To re-appoint Mr. C C Paarthipan (DIN: 01218784) who retires by rotation, and being eligible, offers himself for re-appointment |
| 21-SEP-2023 | AGM | To declare a final dividend Rs. 2.5/- (125%) per equity share of Rs.2 as recommended by the Board of Directors of the company and to ratify the Interim Dividend of Rs.2 (100 %) per equity share of Rs. 2,aggregating to Rs.4.5(225%) for the year ended March 31,2023 |
| 29-SEP-2022 | AGM | To receive, consider and adopt the Audited Standalone and Consolidated Financial Statements of the Company for the Financial Year ended March 31, 2022 along with the Reports of the Board of Directors and the Auditor's thereon. |
| 29-SEP-2022 | AGM | To consider and approve the Re-appointment of Dr Sridhar Ganesan as the Managing Director of the Company |
| 29-SEP-2022 | AGM | Approval for providing loans and guarantees under Section 185 of the Companies Act, 2013 |
| 29-SEP-2022 | AGM | Approval of Material Related Party Transaction(s) with Caplin Steriles Limited |
| 29-SEP-2022 | AGM | Approval of Material Related Party Transaction(s) with NuevosEticos Neo Ethicals S.A - Guatemala |
| 29-SEP-2022 | AGM | Re-appointment of M/s. CNGSN & Associates LLP as the Statutory Auditors of the Company |
| 29-SEP-2022 | AGM | To appoint a Director in place of Dr. Sridhar Ganesan (DIN: 06819026) who retires by rotation, and being eligible, offers himself for re-appointment. |
| 29-SEP-2022 | AGM | To declare a final dividend of Rs. 2/- (100%) per equity share of Rs. 2/- as recommended by the Board of Directors of the Company and to ratify the Interim Dividend of Rs. 2/- (100 %) per equity share of Rs. 2/-, aggregating to Rs. 4 (200%) for the Financial Year ended March 31, 2022. |
FAQs on Caplin Point Laboratories Limited
Disclaimer: The information provided here is for informational purposes only and should not be considered financial advice. Please do your own research and consult with a financial professional before making any investment decisions.